New drug cocktail shows promise for rare brain cancer

NCT ID NCT07350850

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jan 20, 2026 · Last updated May 14, 2026 · Updated 17 times

Summary

This study tests a new combination of four drugs (methotrexate, rituximab, sintilimab, and pirtobrutinib) in people newly diagnosed with primary central nervous system lymphoma (PCNSL), a rare type of brain cancer. The goal is to see if this combo works better than standard treatments at shrinking tumors and improving survival. About 110 adults will take part, and their results will be compared to patients receiving usual care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanxi Provincial People's Hospital
NOT_YET_RECRUITING

Taiyuan, Shanxi, 030012, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
The First Affiliated Hospital of Fujian Medical University
RECRUITING

Xiamen, Fujian, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430000, China

Conditions

Explore the condition pages connected to this study.

PCNSL PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA